{"id":537341,"date":"2021-09-13T08:05:20","date_gmt":"2021-09-13T12:05:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-added-to-ftse-esg-index-series\/"},"modified":"2021-09-13T08:05:20","modified_gmt":"2021-09-13T12:05:20","slug":"i-mab-added-to-ftse-esg-index-series","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-added-to-ftse-esg-index-series\/","title":{"rendered":"I-Mab Added to FTSE ESG Index Series"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span id=\"spanHghlte8fa\"><br \/>\n          <span class=\"xn-location\">SHANGHAI<\/span> and <span class=\"xn-location\">GAITHERSBURG, Md.<\/span><\/span>, <span class=\"xn-chron\">Sept. 13, 2021<\/span> \/PRNewswire\/ &#8212; I-Mab (the &#8220;Company&#8221;) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab will be added to\u00a0the following\u00a0FTSE ESG (Environmental, Social and Governance) Index Series,\u00a0in addition to the FTSE Global Equity Index Series (&#8220;GEIS&#8221;).\u00a0The inclusions below will become effective after market close on <span class=\"xn-chron\">Friday, September 17, 2021<\/span>:<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1433981\/logo_Logo.html\" target=\"_blank\" rel=\"nofollow noopener\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1433981\/logo_Logo.jpg\" title=\"(PRNewsfoto\/I-Mab)\" alt=\"(PRNewsfoto\/I-Mab)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<ul type=\"disc\">\n<li>FTSE Emerging ESG Low Carbon Select Index <\/li>\n<li>FTSE Asia ex Japan ESG Low Carbon Select Index<\/li>\n<\/ul>\n<p>I-Mab strives to be a global leader in ESG standards and practices. In addition to bringing innovative therapies to global patients and creating value for shareholders, the Company has made high corporate governance standards, diversity and inclusivity, green operations, sustainable development and transparent disclosures an integral part of its long-term corporate strategy. In <span class=\"xn-chron\">July 2021<\/span>, I-Mab was granted a BBB rating, the highest newly initiated rating among <span class=\"xn-location\">China<\/span>-based biotech companies, by the MSCI ESG assessment. In <span class=\"xn-chron\">August 2021<\/span>, I-Mab established a new majority independent ESG Committee to set overall ESG strategies for the Company and supervise the implementation of day-to-day ESG workflows by a cross-functional ESG working group.<\/p>\n<p>&#8220;Inclusion in the FTSE ESG Index Series is a strong validation of our track record to promote ESG best practices in our daily work,&#8221; commented Mr. Jielun Zhu, Director and Chief Financial Officer of the Company. &#8220;I-Mab has now been included in the major equity indices around the globe, including the NASDAQ Biotech Index, the MSCI China All Shares Index, and the FTSE Global Equity Index (&#8220;GEIS&#8221;) and FTSE ESG Index Series. On the heels of being added to the FTSE GEIS, this latest index inclusion will further enhance our capital market profile and raise investor recognition.&#8221;<\/p>\n<p>FTSE Russell is a global index leader that provides innovative benchmarking, analytics, and data solutions for investors worldwide. The FTSE Russell&#8217;s ESG ratings measure the overall quality of a company&#8217;s management of ESG issues and are comprised of an overall rating that breaks down into 3 pillars including\u00a0 Environmental, Social, Governance and 14 themes including Biodiversity,\u00a0Climate Change,\u00a0Pollution and Resources,\u00a0Supply Chain,\u00a0Water Security, Customer Responsibility, Health and Safety, Human Rights and Community, Labor Standards, Supply Chain, Anti-Corruption, Corporate Governance, Risk Management, and Tax Transparency, built on over 300 individual indicator assessments that are applied to each company&#8217;s unique ESG risk exposures. It is designed to align investment and ESG objectives into a broad benchmark. For more information, please refer to the Index page on FTSE&#8217;s website at <a target=\"_blank\" href=\"https:\/\/www.ftserussell.com\/products\/indices\/esg\" rel=\"nofollow noopener\">https:\/\/www.ftserussell.com\/products\/indices\/esg<\/a><\/p>\n<p>\n        <b>About I-Mab<\/b>\n      <\/p>\n<p>I-Mab (Nasdaq: IMAB) is an innovation-driven global biotech company focusing on discovery, development and soon commercialization of novel and highly differentiated biologics in immuno-oncology therapeutic area. The Company&#8217;s mission is to bring transformational medicines to patients around the world through drug innovation. I-Mab&#8217;s globally competitive pipeline of more than 15 clinical and pre-clinical stage drug candidates is driven by its internal R&amp;D capability and global licensing partnerships, based on the Company&#8217;s unique Fast-to-Proof-of-Concept and Fast-to-Market pipeline development strategies. The Company is now rapidly progressing from a clinical stage biotech company to a fully integrated global biopharmaceutical company with cutting-edge global R&amp;D capabilities, a world-class GMP manufacturing facility and commercialization capability. I-Mab has established its global footprint in <span class=\"xn-location\">Shanghai<\/span> (headquarters), <span class=\"xn-location\">Beijing<\/span>, <span class=\"xn-location\">Hangzhou<\/span>, <span class=\"xn-location\">Guangzhou<\/span>, Lishui and <span class=\"xn-location\">Hong Kong<\/span> in <span class=\"xn-location\">China<\/span>, and <span class=\"xn-location\">Maryland<\/span> and <span class=\"xn-location\">San Diego<\/span> in <span class=\"xn-location\">the United States<\/span>. For more information, please visit <a href=\"http:\/\/ir.i-mabbiopharma.com\" rel=\"nofollow\">http:\/\/ir.i-mabbiopharma.com<\/a> and follow I-Mab on <a target=\"_blank\" href=\"https:\/\/www.linkedin.com\/company\/i-mab\/\" rel=\"nofollow noopener\">LinkedIn<\/a>, <a target=\"_blank\" href=\"https:\/\/twitter.com\/IMabBiopharma\" rel=\"nofollow noopener\">Twitter<\/a> and <a target=\"_blank\" href=\"https:\/\/mp.weixin.qq.com\/s\/_s634aizyQPuq1Vgf-hLGA\" rel=\"nofollow noopener\">WeChat<\/a>.<\/p>\n<p>\n        <b>Forward Looking Statements<\/b>\n      <\/p>\n<p>This press release includes certain disclosures which contain &#8220;forward-looking statements.&#8221; You can identify forward-looking statements because they contain words such as &#8220;anticipate&#8221; and &#8220;expected.&#8221; Forward-looking statements are based on I-Mab&#8217;s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in filings with the U.S. Securities and Exchange Commission. I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.<\/p>\n<p>\n        <b>For more information, please contact:<\/b>\n      <\/p>\n<p>\n        <b>I-Mab<\/b>\n      <\/p>\n<p>Jielun Zhu, Chief Financial Officer<br \/>E-mail: <a target=\"_blank\" href=\"mailto:jielun.zhu@i-mabbiopharma.com\" rel=\"nofollow noopener\">jielun.zhu@i-mabbiopharma.com<\/a><br \/>Office line: +86 21 6057 8000<\/p>\n<p>\n        <span class=\"xn-person\">Gigi Feng<\/span>, Chief Communications Officer<br \/>E-mail: <a target=\"_blank\" href=\"mailto:gigi.feng@i-mabbiopharma.com\" rel=\"nofollow noopener\">gigi.feng@i-mabbiopharma.com<\/a><br \/>Office line: +86 21 6057 5709<\/p>\n<p>\n        <b>Investor Inquiries:<\/b>\n      <\/p>\n<p>The Piacente Group, Inc.<br \/><span class=\"xn-person\">Emilie Wu<\/span><br \/>E-mail: <a target=\"_blank\" href=\"mailto:emilie@thepiacentegroup.com\" rel=\"nofollow noopener\">emilie@thepiacentegroup.com<\/a><br \/>Office line: + 86 21 6039 8363<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN04342&amp;sd=2021-09-13\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow noopener\" href=\"https:\/\/www.prnewswire.com\/news-releases\/i-mab-added-to-ftse-esg-index-series-301375068.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/i-mab-added-to-ftse-esg-index-series-301375068.html<\/a><\/p>\n<p>SOURCE  I-Mab<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=CN04342&amp;Transmission_Id=202109130800PR_NEWS_USPR_____CN04342&amp;DateId=20210913\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SHANGHAI and GAITHERSBURG, Md., Sept. 13, 2021 \/PRNewswire\/ &#8212; I-Mab (the &#8220;Company&#8221;) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab will be added to\u00a0the following\u00a0FTSE ESG (Environmental, Social and Governance) Index Series,\u00a0in addition to the FTSE Global Equity Index Series (&#8220;GEIS&#8221;).\u00a0The inclusions below will become effective after market close on Friday, September 17, 2021: FTSE Emerging ESG Low Carbon Select Index FTSE Asia ex Japan ESG Low Carbon Select Index I-Mab strives to be a global leader in ESG standards and practices. In addition to bringing innovative therapies to global patients and creating value for shareholders, the Company has made high corporate governance standards, diversity &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-added-to-ftse-esg-index-series\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;I-Mab Added to FTSE ESG Index Series&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-537341","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>I-Mab Added to FTSE ESG Index Series - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-added-to-ftse-esg-index-series\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"I-Mab Added to FTSE ESG Index Series - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SHANGHAI and GAITHERSBURG, Md., Sept. 13, 2021 \/PRNewswire\/ &#8212; I-Mab (the &#8220;Company&#8221;) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab will be added to\u00a0the following\u00a0FTSE ESG (Environmental, Social and Governance) Index Series,\u00a0in addition to the FTSE Global Equity Index Series (&#8220;GEIS&#8221;).\u00a0The inclusions below will become effective after market close on Friday, September 17, 2021: FTSE Emerging ESG Low Carbon Select Index FTSE Asia ex Japan ESG Low Carbon Select Index I-Mab strives to be a global leader in ESG standards and practices. In addition to bringing innovative therapies to global patients and creating value for shareholders, the Company has made high corporate governance standards, diversity &hellip; Continue reading &quot;I-Mab Added to FTSE ESG Index Series&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-added-to-ftse-esg-index-series\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-13T12:05:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1433981\/logo_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-added-to-ftse-esg-index-series\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-added-to-ftse-esg-index-series\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"I-Mab Added to FTSE ESG Index Series\",\"datePublished\":\"2021-09-13T12:05:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-added-to-ftse-esg-index-series\\\/\"},\"wordCount\":783,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-added-to-ftse-esg-index-series\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1433981\\\/logo_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-added-to-ftse-esg-index-series\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-added-to-ftse-esg-index-series\\\/\",\"name\":\"I-Mab Added to FTSE ESG Index Series - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-added-to-ftse-esg-index-series\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-added-to-ftse-esg-index-series\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1433981\\\/logo_Logo.jpg\",\"datePublished\":\"2021-09-13T12:05:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-added-to-ftse-esg-index-series\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-added-to-ftse-esg-index-series\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-added-to-ftse-esg-index-series\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1433981\\\/logo_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1433981\\\/logo_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-added-to-ftse-esg-index-series\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"I-Mab Added to FTSE ESG Index Series\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"I-Mab Added to FTSE ESG Index Series - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-added-to-ftse-esg-index-series\/","og_locale":"en_US","og_type":"article","og_title":"I-Mab Added to FTSE ESG Index Series - Market Newsdesk","og_description":"PR Newswire SHANGHAI and GAITHERSBURG, Md., Sept. 13, 2021 \/PRNewswire\/ &#8212; I-Mab (the &#8220;Company&#8221;) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab will be added to\u00a0the following\u00a0FTSE ESG (Environmental, Social and Governance) Index Series,\u00a0in addition to the FTSE Global Equity Index Series (&#8220;GEIS&#8221;).\u00a0The inclusions below will become effective after market close on Friday, September 17, 2021: FTSE Emerging ESG Low Carbon Select Index FTSE Asia ex Japan ESG Low Carbon Select Index I-Mab strives to be a global leader in ESG standards and practices. In addition to bringing innovative therapies to global patients and creating value for shareholders, the Company has made high corporate governance standards, diversity &hellip; Continue reading \"I-Mab Added to FTSE ESG Index Series\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-added-to-ftse-esg-index-series\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-13T12:05:20+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1433981\/logo_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-added-to-ftse-esg-index-series\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-added-to-ftse-esg-index-series\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"I-Mab Added to FTSE ESG Index Series","datePublished":"2021-09-13T12:05:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-added-to-ftse-esg-index-series\/"},"wordCount":783,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-added-to-ftse-esg-index-series\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1433981\/logo_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-added-to-ftse-esg-index-series\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-added-to-ftse-esg-index-series\/","name":"I-Mab Added to FTSE ESG Index Series - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-added-to-ftse-esg-index-series\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-added-to-ftse-esg-index-series\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1433981\/logo_Logo.jpg","datePublished":"2021-09-13T12:05:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-added-to-ftse-esg-index-series\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-added-to-ftse-esg-index-series\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-added-to-ftse-esg-index-series\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1433981\/logo_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1433981\/logo_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-added-to-ftse-esg-index-series\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"I-Mab Added to FTSE ESG Index Series"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/537341","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=537341"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/537341\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=537341"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=537341"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=537341"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}